A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01

BACKGROUND: Pediatric low-grade gliomas (PLGG) are the most frequent brain tumors in children. Up to 50% will be refractory to conventional chemotherapy. It is now known that the majority of PLGG have activation of the MAPK/ERK pathway. The same pathway is also activated in plexiform neurofibromas (...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Cancer
Hlavní autoři: Perreault, Sébastien, Larouche, Valérie, Tabori, Uri, Hawkin, Cynthia, Lippé, Sarah, Ellezam, Benjamin, Décarie, Jean-Claude, Théoret, Yves, Métras, Marie-Élaine, Sultan, Serge, Cantin, Édith, Routhier, Marie-Ève, Caru, Maxime, Legault, Geneviève, Bouffet, Éric, Lafay-Cousin, Lucie, Hukin, Juliette, Erker, Craig, Jabado, Nada
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2019
Témata:
Study Protocol
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6935133/
https://ncbi.nlm.nih.gov/pubmed/31881853
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-6442-2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky